Resmed Inc DRC (RSMDF)

Healthcare · Medical Instruments & Supplies
$22.61 +0.00% on the day Market cap $49.6B 52-week range $11.85 to $28.25 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
10% a year for 10 years

At a market value of $49.6B, Resmed Inc DRC's free cash flow of $1.6B (fiscal 2026) would need to grow about 10% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Resmed Inc DRC's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price10.3% a year
Free cash flow, last 9 years18.7% a year
Revenue, same period11.8% a year
Price to free cash flow30.1x

Fundamental grade

B

Five factors scored 1 to 9 from RSMDF's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation4
Profitability9
Growth5
Financial health8
Cash efficiency9

Key numbers

P/E (trailing)32.9x
P/E (forward)28.9x
Price / free cash flow29.9x
EV / EBITDA25.0x
Price / sales8.78x
Price / book7.64x
Revenue growth+8.6%
Operating margin33.4%
Net margin26.9%
Return on equity23.1%
Dividend yield6.9%
Debt / equity0.36x

Results from SEC filings

Fiscal years, from Resmed Inc DRC's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20222023202420252026
Revenue$3.6B$4.2B$4.7B$5.1B$5.7B
Net income$779M$898M$1.0B$1.4B$1.5B
Free cash flow$216M$574M$1.3B$1.7B$1.6B
EPS (diluted)$5.30$6.09$6.92$9.51$10.43
Operating margin28.0%26.8%28.2%32.7%33.4%

Where the revenue comes from

Revenue by segments, fiscal 2026.

Sleep and Breathing Health$5.0B88%
Residential Care Software$676M12%

Superinvestors who own RSMDF

From each investor's latest 13F filing (what a 13F shows).

None of the superinvestors we track held RSMDF in their latest 13F.

Insider buying

Open-market purchases by Resmed Inc DRC's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of RSMDF in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when RSMDF trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Resmed Inc DRC's stock price imply?

At a market value of $49.6B, Resmed Inc DRC would need its free cash flow to grow about 10% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 19% a year.

Are Resmed Inc DRC insiders buying the stock?

No open-market insider purchases of RSMDF in the last 12 months, according to SEC Form 4 filings.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.